久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Samus Therapeutics Launches PU-AD Clinical Program in Alzheimer's Disease americanpharmaceuticalreview
    July 25, 2019
    Samus Therapeutics announced the initiation of its clinical program for PU-AD, an oral, brain permeable inhibitor of epichaperomes in Alzheimer's Disease (AD) following clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug
  • Samus Therapeutics Launches PU-AD Clinical Program in Alzheimer's Disease americanpharmaceuticalreview
    July 24, 2019
    Samus Therapeutics announced the initiation of its clinical program for PU-AD, an oral, brain permeable inhibitor of epichaperomes in Alzheimer's Disease (AD) following clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug
PharmaSources Customer Service